

## Plasma assay promising for diagnosis of early Alzheimer disease

August 2 2019



(HealthDay)—Plasma  $\beta$ -amyloid (A $\beta$ )42/A $\beta$ 40 corresponds with



amyloid positron emission tomography (PET) status, according to a study published online Aug. 1 in *Neurology*.

Suzanne E. Schindler, M.D., Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues measured A\u03c642/A\u03c640 in plasma and <u>cerebrospinal fluid</u> (CSF) samples obtained from 158 mostly cognitively normal individuals within 18 months of an amyloid PET scan.

The researchers identified high correspondence for plasma A $\beta$ 42/A $\beta$ 40 with amyloid PET status (receiver operating characteristic area under the curve [AUC], 0.88) and CSF p-tau181/A $\beta$ 42 (AUC, 0.85). There was a very high correspondence for the combination of plasma A $\beta$ 42/A $\beta$ 40, age, and *APOE*  $\epsilon$ 4 status with amyloid PET (AUC, 0.94). Compared with individuals with a negative plasma A $\beta$ 42/A $\beta$ 40, those with a negative amyloid PET scan at baseline and a positive plasma A $\beta$ 42/A $\beta$ 40 had a 15-fold higher risk for conversion to amyloid PET-positive.

"More comprehensive studies are currently underway to further validate this assay in multiple large international cohorts," the authors write. "If further validated, this assay will accelerate progress towards an effective therapy for Alzheimer disease by decreasing the time, cost, and risk of drug trials, and one day enable a <u>blood test</u> in the clinic to identify patients who could benefit from disease-modifying treatment."

Several authors disclosed financial ties to biopharmaceutical companies, including Eli Lilly/Avid Radiopharmaceuticals, which provided partial financial support. Two authors have submitted a provisional patent application.

More information: <u>Abstract/Full Text (subscription or payment may</u> <u>be required)</u> <u>Editorial (subscription or payment may be required)</u>



## Copyright © 2019 <u>HealthDay</u>. All rights reserved.

Citation: Plasma assay promising for diagnosis of early Alzheimer disease (2019, August 2) retrieved 10 July 2023 from <u>https://medicalxpress.com/news/2019-08-plasma-assay-diagnosis-early-alzheimer.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.